S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
3 Secrets To Consistent Trading Success (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
BREAKING: Tiny biotech successfully treats blindness (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Buy THIS stock before Taiwan is attacked (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
3 Secrets To Consistent Trading Success (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
BREAKING: Tiny biotech successfully treats blindness (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Buy THIS stock before Taiwan is attacked (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
3 Secrets To Consistent Trading Success (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
BREAKING: Tiny biotech successfully treats blindness (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Buy THIS stock before Taiwan is attacked (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
3 Secrets To Consistent Trading Success (Ad)pixel
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
BREAKING: Tiny biotech successfully treats blindness (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
Buy THIS stock before Taiwan is attacked (Ad)
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
NYSEAMERICAN:VNRX

VolitionRx - VNRX Stock Forecast, Price & News

$1.91
-0.01 (-0.52%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.88
▼
$1.96
50-Day Range
N/A
52-Week Range
$1.31
▼
$3.30
Volume
68,966 shs
Average Volume
150,811 shs
Market Capitalization
$111.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67

VolitionRx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
196.7% Upside
$5.67 Price Target
Short Interest
Healthy
1.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$409,500 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

See Top Rated MarketRank™ Stocks Here

VNRX stock logo

About VolitionRx (NYSEAMERICAN:VNRX) Stock

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

VNRX Stock News Headlines

March 21, 2023 | markets.businessinsider.com
Maxim Group Sticks to Their Buy Rating for VolitionRX (VNRX)
March 20, 2023 | benzinga.com
VolitionRX Stock (AMEX:VNRX), Guidance and Forecast
April 1, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
March 10, 2023 | finance.yahoo.com
VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business Update
March 6, 2023 | finance.yahoo.com
VolitionRx Limited to Webcast Live at VirtualInvestorConferences.com March 9th
February 27, 2023 | finance.yahoo.com
VNRX: Nu.Q Vet Cancer Test Being Launched by Supply Agreement Partners Heska and IDEXX; 4.945 million Share Offering Completed to Help Fund Management’s Initiatives
February 22, 2023 | finance.yahoo.com
VolitionRx Limited Announces Closing of $8.7 Million Underwritten Public Offering of Common Stock
February 17, 2023 | finance.yahoo.com
VolitionRx Limited Announces Pricing of $7.525 Million Underwritten Public Offering of Common Stock
April 1, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
February 16, 2023 | finance.yahoo.com
Volition's Nu.Q® Vet Cancer Test Now Available for Pre-Order at The Point-of-Care Through Heska Corporation
January 8, 2023 | finance.yahoo.com
Volition Issues Business Review 2022
November 14, 2022 | finance.yahoo.com
VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update
November 14, 2022 | finance.yahoo.com
Volition Announces Clinical Research Study with Oncovet
November 10, 2022 | finance.yahoo.com
Volition to Participate in a Lung Cancer Screening Study in France
October 20, 2022 | benzinga.com
Volition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test - VolitionRX (AMEX:VNRX) - Benzinga
October 20, 2022 | nasdaq.com
VolitionRx Signs Global Supply Deal For Nu.Q Vet Cancer Test - Nasdaq
October 20, 2022 | finance.yahoo.com
Volition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test
October 11, 2022 | finance.yahoo.com
Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics - Yahoo Finance
September 12, 2022 | proactiveinvestors.com
NA Proactive news snapshot: Unrivaled Brands, Steppe Gold, Quantum eMotion, First Mining Gold, Co-Diagnostics, Doré Copper Mining, Todos Medical UPDTE... - Proactive Investors USA
September 12, 2022 | globenewswire.com
VolitionRx Limited to Webcast Live at VirtualInvestorConferences.com September 15th - GlobeNewswire
August 16, 2022 | finance.yahoo.com
Volition Appoints Mickie Henshall as an Independent Director
August 11, 2022 | greenwichtime.com
VolitionRX: Q2 Earnings Snapshot - Greenwich Time
August 11, 2022 | proactiveinvestors.com
VolitionRX announces 2nd quarter financials as company look to accelerate growth - Proactive Investors USA
August 11, 2022 | seekingalpha.com
VolitionRX Q2 2022 Earnings Preview (NYSE:VNRX) - Seeking Alpha
August 10, 2022 | proactiveinvestors.com
NA Proactive news snapshot: Banxa Holdings, Xeris Biopharma, VolitionRx Limited, TRACON Pharmaceuticals, Etruscus Resources UPDATE ... - Proactive Investors USA
August 10, 2022 | seekingalpha.com
VolitionRX reports Q2 results (NYSE:VNRX) - Seeking Alpha
August 10, 2022 | finance.yahoo.com
VolitionRx Limited Announces Second Quarter 2022 Financial Results and Business Update
See More Headlines
Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

VNRX Company Calendar

Last Earnings
11/10/2021
Today
4/01/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:VNRX
Previous Symbol
NYSEMKT:VNRX
CUSIP
N/A
CIK
N/A
Web
www.volitionrx.com
Phone
(646) 650-1351
Fax
65 32 8172 5651
Employees
65
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.67
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+196.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.57)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-26,820,000.00
Net Margins
-15,452.74%
Pretax Margin
-15,607.46%
Return on Equity
-350.45%
Return on Assets
-116.26%

Debt

Debt-to-Equity Ratio
0.94
Current Ratio
1.04
Quick Ratio
1.04

Sales & Book Value

Annual Sales
$90,000.00
Price / Sales
1,233.86
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.33 per share
Price / Book
5.79

Miscellaneous

Outstanding Shares
58,140,000
Free Float
48,838,000
Market Cap
$111.05 million
Optionable
Not Optionable
Beta
1.73

Key Executives

  • Cameron John Reynolds
    President, Chief Executive Officer & Director
  • Gaetan Michel
    Chief Operating Officer
  • Terig Hughes
    Chief Financial Officer & Treasurer
  • Jacob Vincent Micallef
    Chief Scientific Officer
  • Terry Kelly
    Chief Innovation Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VNRX Stock - Frequently Asked Questions

Should I buy or sell VolitionRx stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VNRX shares.
View VNRX analyst ratings or view top-rated stocks.

What is VolitionRx's stock price forecast for 2023?

3 analysts have issued 1-year price targets for VolitionRx's stock. Their VNRX share price forecasts range from $5.00 to $6.00. On average, they anticipate the company's stock price to reach $5.67 in the next twelve months. This suggests a possible upside of 196.7% from the stock's current price.
View analysts price targets for VNRX or view top-rated stocks among Wall Street analysts.

When is VolitionRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our VNRX earnings forecast.

How were VolitionRx's earnings last quarter?

VolitionRx Limited (NYSEAMERICAN:VNRX) released its earnings results on Wednesday, November, 10th. The medical research company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. The medical research company earned $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. VolitionRx had a negative net margin of 15,452.74% and a negative trailing twelve-month return on equity of 350.45%.

What other stocks do shareholders of VolitionRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VolitionRx investors own include Chesapeake Energy (CHKAQ), Bausch Health Companies (BHC), Verastem (VSTM), Exelixis (EXEL), Protalix BioTherapeutics (PLX), Rigel Pharmaceuticals (RIGL), CRISPR Therapeutics (CRSP), TherapeuticsMD (TXMD), ADMA Biologics (ADMA) and Bausch Health Companies (BHC).

What is VolitionRx's stock symbol?

VolitionRx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

How do I buy shares of VolitionRx?

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VolitionRx's stock price today?

One share of VNRX stock can currently be purchased for approximately $1.91.

How much money does VolitionRx make?

VolitionRx (NYSEAMERICAN:VNRX) has a market capitalization of $111.05 million and generates $90,000.00 in revenue each year. The medical research company earns $-26,820,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.

How can I contact VolitionRx?

VolitionRx's mailing address is 13215 BEE CAVE PARKWAY GALLERIA OAKS B SUITE 125, AUSTIN TX, 78738. The official website for the company is www.volitionrx.com. The medical research company can be reached via phone at (646) 650-1351, via email at investorrelations@volition.com, or via fax at 65 32 8172 5651.

This page (NYSEAMERICAN:VNRX) was last updated on 4/1/2023 by MarketBeat.com Staff